Dr. Charles M. Rudin, MD, PhD

Dr. Rudin practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Rudin's NPI, 1467483404, was assigned on July 6, 2006. Dr. Rudin graduated from Pritzker School of Medicine in 1993. Dr. Rudin's Maryland license number on file is D61040.

Dr. Rudin's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Rudin's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rudin practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Rudin's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Rudin is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Rudin's licenses on file in 5 states: Maryland, Florida, New York, New Jersey and Illinois.

Dmand AI lists lung cancer among the conditions Dr. Rudin treats.

CMS data shows 253 Medicare services from Dr. Rudin across 3 procedure codes in 2024, all of them office visits, for 83 Medicare patients. Medicare paid $31,563 for them. Every service was in an office.

CMS counts 83 Medicare patients who saw Dr. Rudin in 2024. The largest group is 75 to 84, with 36 patients. 75% of them have cancer, and 75% have high blood pressure. 14% are also on Medicaid. Their average risk score is 3.12, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rudin's median patient age at 72, with 63% women.

In 2024, Dr. Rudin wrote 362 Medicare Part D claims for 51 patients. 67% of them were for generic drugs. CMS names the drug for 213 of them, across 8 drugs with 11 or more claims each, at $562,845 in total drug cost. In 2023, CMS named 307 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 76 out of 100 for Dr. Rudin for performance year 2024, reported as part of a group. Dr. Rudin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rudin as offering telehealth.

Dmand AI links 454 papers to Dr. Rudin, published from 2003 to 2025. 2019 was the busiest year, with 38. The most frequent topics are Lung Neoplasms, Small Cell Lung Carcinoma and Carcinoma, Non-Small-Cell Lung. Dr. Rudin has published most often in Clin Cancer Res. Dr. Rudin's most frequent co-authors are Mark G. Kris, MD, Matthew D. Hellmann, MD and Gregory J. Riely, MD.

Dmand AI links Dr. Rudin to 16 clinical trials, 6 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Small Cell Lung Carcinoma and Carcinoma, Non-Small-Cell Lung. National Cancer Institute (NCI) sponsors the most, 6.

CMS Open Payments shows 247 general payments to Dr. Rudin from 28 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 81% of the total. Genentech, Inc. paid the most, $41,320. It also lists 2 research payments totaling $2,339 from 2023 to 2025.

Dmand AI lists 1 award for Dr. Rudin, most recently ASCI Member in 2010.

Dr. Rudin graduated from Pritzker School of Medicine in 1993.

Dr. Rudin is in network with 13 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.